Emoxypine Succinate

Clinical studies showed emoxypine results in a rapid recovery from Sciatica by the spinal and peripheral nerves with a significant reduction in severity of pain going down the leg from the lower back. Emoxypine succinate works by protecting neurons against free radicals, this is a different pathway than traditional nootropics. Emoxypine (Mexidol) is an antioxidant similar to vitamin B6 with anxiolytic, anti-stress, anti-alcohol, anticonvulsant, nootropic, neuroprotective and anti-inflammatory effects make it a no brainer (pun intended). Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine) helps with cerebral blood flow, inhibits brain blood clots (stroke) , lowers cholesterol levels and is cardioprotective. Emoxypine Review In 2017, a randomized, double-blind, placebo-controlled study was conducted to evaluate the safety and efficacy of Emoxypine. 151 patients with a history of ischemic stroke were enrolled and assigned to two groups: the first received 500 mg/day by IV, for 10 days, followed by 125mg, three times daily, for 8 weeks. In 2017, a randomized, double-blind, placebo-controlled study was conducted to evaluate the safety and efficacy of Emoxypine. 151 patients with a history of ischemic stroke were enrolled and assigned to two groups: the first received 500 mg/day by IV, for 10 days, followed by 125mg, three times daily, for 8 weeks. The results showed a statistically significant improvements in quality of life and movement, no adverse effects were recorded In a 2016 study, the antihypoxic efficacy of Emoxypine during carotid endarterectomy (CE) procedure was examined in 54 patients with cerebral atherosclerotic stenosis. The results showed that Emoxypine significantly reduces brain hypoxia, the overall time of surgery, and the neurological and psychological status of patients, post-surgery. A 2014 study examined the effects of Emoxypine-containing toothpaste and mouthwash on participants with xerostomia (excessively dry mouth) symptoms. Results showed that, after one year of use, the experimental group had 2.7 times lower reported oral mucosa disorders. In a 2016 study, Russian researchers conducted a study to explore the effects of Emoxypine on 110 patients with primary hypothyroidism. Neurological and psychological outcomes were measured and electroneuromyography was performed to assess the status of the peripheral nervous system. Significant positive effects were recorded for all parameters in the experimental group. A 2013 study of anticonvulsant effects examined 75 participants with symptomatic focal posttraumatic epilepsy. They were administered a combination of Emoxypine and phenotropil (Phenibut). The results showed a significant reduction in the number of seizures as well as improvements in quality of life and cognitive performance. This is reportedly in contrast to most nootropics, which typically aggravate seizures. Another study in 2013 used a combination of 100 – 300 mg Emoxypine with 150 mg picamilon to examine the effects in patients with primary open-angle glaucoma (POAG), over a period of 14-21 days. Results showed improvements in visual acuity and increased blood flow in the central retinal artery, for the experimental groups. The effects of antidepressant medication alone and in combination with Emoxypine was studied in 70 patients with panic disorder and insomnia. After two weeks of treatment, results showed a significant difference in anxiolytic and sleep-promoting effects between the two groups, with the combination treatment having better outcomes. Anti-inflammatory effects were studied in a group of patients with rheumatoid arthritis. After two weeks of treatment, the experimental group showed improvements in inflammation markers, as well as quality of life and a reduction in depressive symptoms.